Trial · NCT01318694
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants Who Achieved Sustained Virologic Response (SVR) 12 Weeks After the End of Treatment (SVR12) | 12 weeks after the end of treatment | Full Analysis Set | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Who Achieved SVR 24 Weeks After the End of Treatment (SVR24) | 24 weeks after the end of treatment | Participants in the Full Analysis Set with available data | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Rapid Virologic Response (RVR) After 4 Weeks of Treatment (RVR4) | after 4 weeks of treatment | Participants in the Full Analysis Set with available data | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Early Virologic Response (EVR) After 12 Weeks of Treatment | after 12 weeks of treatment | Participants in the Full Analysis Set with available data | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Partial Early Virologic Response (pEVR) After 12 Weeks of Treatment | after 12 weeks of treatment | Participants in the Full Analysis Set with available data | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Complete Early Virologic Response (cEVR) After 12 Weeks of Treatment | after 12 weeks of treatment | Participants in the Full Analysis Set with available data | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Extended Rapid Virologic Response (eRVR) From 4 to 12 Weeks of Treatment | from 4 to 12 weeks of treatment | Participants in the Full Analysis Set with available data | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With End of Treatment Response (ETR) at Treatment End Within 48 Weeks | at treatment end within 48 weeks | Participants in the Full Analysis Set with available data | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Alanine Aminotransferase (ALT) Abnormalities Within 48 Weeks | within 48 weeks | Participants in the Safety Set, defined as having received at least one dose of study medication, with available data | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Grade 3 or 4 Anemia During Treatment Within 48 Weeks | within 48 weeks | Participants in the Safety Set with available data | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Grade 3 or 4 Neutropenia During Treatment Within 48 Weeks | within 48 weeks | Participants in the Safety Set with available data | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Grade 3 or 4 Thrombocytopenia During Treatment Within 48 Weeks | within 48 weeks | Participants in the Safety Set with available data | percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01318694/outcomes